Predictors of Spontaneous Bacterial Peritonitis Among Patients with Cirrhosis
Launched by ASSIUT UNIVERSITY · Mar 13, 2025
Trial Information
Current as of April 30, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a specific condition called spontaneous bacterial peritonitis (SBP) in patients who have liver cirrhosis and fluid buildup in the abdomen (ascites). The researchers want to create a simple scoring system that can predict the risk of developing SBP and related complications, especially in older patients. They will look at several factors, such as age, certain blood cell measurements, and inflammation markers to help identify those at higher risk. Early detection is crucial because it can lower the chances of severe outcomes, including death.
To participate in this trial, potential participants must be adults aged between 18 and 70 with cirrhosis and significant ascites. They should not have other infections, certain medical conditions, or have received specific treatments recently. If eligible, participants can expect to provide blood samples and undergo assessments to help the researchers understand the relationship between these factors and SBP. This study aims to improve how doctors can identify and treat patients at risk for SBP, ultimately enhancing patient care and outcomes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • include cirrhotic patients with Moderate-marked ascites, as determined by abdominal ultrasonography (US). SBP will be diagnosed based on detection of polymorph nuclear leukocytes (PMNs) \>250 cells/mcL and/or white blood cells (WBCs) \>500 cells/mcL by ascitic fluid examination.
- Exclusion Criteria:
- • 1- Pediatric patients (less than 18 years old) and patients older than 70 years Pregnant patients .
- • 2-Etiology of ascites other than cirrhosis. 3-Receiving antibiotics and/or prophylaxis four weeks before admission. 4- Concurrent bacterial infection other than SBP. 5- Abdominal surgery 12 weeks before admission 6-Patients with neoplastic or hematological disease. 7- Patients who received bone marrow transplantation, chemotherapy, or radiotherapy four weeks before admission.
- • 8- Conditions associated with increased MPV such as systemic hypertension, diabetes mellitus, dyslipidemia, peripheral vascular disease, thyroid disease, and therapy four weeks before admission with antiplatelet agents and nonsteroidal anti-inflammatory drugs
About Assiut University
Assiut University, a prominent academic institution located in Egypt, is dedicated to advancing medical research and clinical trials that enhance healthcare outcomes. With a strong emphasis on innovation and collaboration, the university engages in a wide array of clinical studies across various disciplines, aiming to contribute valuable insights into disease prevention, diagnosis, and treatment. Assiut University's commitment to ethical research practices and rigorous scientific methodology ensures the integrity and reliability of its clinical trials, ultimately benefiting both the local community and the global medical landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported